NICE, the health technology appraisal institute for England and Wales, has said a preliminary no to Novartis' Lucentis (ranibizumab) for patients with visual impairment due to diabetic macular oedema (DMO) for use on the National Health Service. The firm had presented a "faulty" economic analysis that failed to reflect UK clinical practice, said NICE.
Today's appraisal consultation document (ACD) comes just two months after Novartis secured EU approval for the VEGF receptor antagonist for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?